BRAF and metastatic malignant neoplasm in the lymph nodes: The BRAF V600E AF has recently been implicated in the metastatic potential of PTC, with studies suggesting that higher AF is associated with poorer clinical outcomes and advanced tumor staging due to increased invasiveness and lymph node metastases [12].